Abstract
The use of anti-gene agents to disrupt the expression of disease-related genes could potentially be of utility in the treatment of a large number of illnesses, including most neoplasms. Traditional anti-gene agents include antisense oligonucleotides and ribozymes. Recent observations have provided evidence for another promising anti-gene technology-RNA interference (RNAi), in which the introduced double-stranded RNA (dsRNA), after a complicated series of processing steps, disrupts the expression of the targeted cellular gene. Further studies have indicated that small interfering RNAs (siRNAs) of generally 21 ∼ 23 nucleotides, which resemble the processing products of long dsRNA, can induce RNAi directly in mammalian cells. Because of their high specificity and efficiency, siRNAs might be a new class of anti-gene medicines for gene therapy applications.
Keywords: Gene Therapy, anti-gene medicines, oligonucleotides, ribozymes
Current Gene Therapy
Title: Small Interfering RNA: A New Tool for Gene Therapy
Volume: 3 Issue: 5
Author(s): Feng Bi, Na Liu and Daiming Fan
Affiliation:
Keywords: Gene Therapy, anti-gene medicines, oligonucleotides, ribozymes
Abstract: The use of anti-gene agents to disrupt the expression of disease-related genes could potentially be of utility in the treatment of a large number of illnesses, including most neoplasms. Traditional anti-gene agents include antisense oligonucleotides and ribozymes. Recent observations have provided evidence for another promising anti-gene technology-RNA interference (RNAi), in which the introduced double-stranded RNA (dsRNA), after a complicated series of processing steps, disrupts the expression of the targeted cellular gene. Further studies have indicated that small interfering RNAs (siRNAs) of generally 21 ∼ 23 nucleotides, which resemble the processing products of long dsRNA, can induce RNAi directly in mammalian cells. Because of their high specificity and efficiency, siRNAs might be a new class of anti-gene medicines for gene therapy applications.
Export Options
About this article
Cite this article as:
Bi Feng, Liu Na and Fan Daiming, Small Interfering RNA: A New Tool for Gene Therapy, Current Gene Therapy 2003; 3 (5) . https://dx.doi.org/10.2174/1566523034578203
DOI https://dx.doi.org/10.2174/1566523034578203 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Options and Treatment Strategies Against COVID-19 in China
Current Organic Synthesis A Simplified Protocol for Routine Chemoselective Syntheses of Piperazines Substituted in the 1-Position by an Electron Withdrawing Group
Current Organic Synthesis Low Molecular Weight Heparins as Antineoplastic Agents
Recent Patents on Anti-Cancer Drug Discovery Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Chronopharmaceutical Delivery of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tissue-Specific Targeting for Cardiovascular Gene Transfer. Potential Vectors and Future Challenges
Current Gene Therapy New Therapeutic Strategies for Coeliac Disease: Tissue Transglutaminase as a Target
Current Medicinal Chemistry Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Microgravity and Mesenchymal Stem Cell Response
Current Biotechnology Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Runx2/Cbfa1: A Multifunctional Regulator of Bone Formation
Current Pharmaceutical Design Encephalopathy: A Vicious Cascade Following Forebrain Ischemia and Hypoxia
Central Nervous System Agents in Medicinal Chemistry The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy
Current Drug Targets Aqueous Two-phase Extraction in Downstream Processing
Current Biochemical Engineering (Discontinued) The Role of miRNAs in Cartilage Homeostasis
Current Genomics Lanthionine Synthetase Component C-Like Protein 2: A New Drug Target for Inflammatory Diseases and Diabetes
Current Drug Targets Remodeling of the Myocardium and Potential Targets in the Collagen Degradation and Synthesis Pathways
Current Drug Targets - Cardiovascular & Hematological Disorders Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry A New Combined Therapeutic Strategy of Governor Vessel Electro-Acupuncture and Adult Stem Cell Transplantation Promotes the Recovery of Injured Spinal Cord
Current Medicinal Chemistry Prayer at Midlife is Associated with Reduced Risk of Cognitive Decline in Arabic Women
Current Alzheimer Research